Preclinical Research Division, Bio-K Plus International Inc, Laval, Quebec, Canada.
Clin Infect Dis. 2015 May 15;60 Suppl 2:S135-43. doi: 10.1093/cid/civ179.
A specific probiotic formulation composed of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+) has been marketed in North America since 1996. The strains and the commercial products have been evaluated for safety, identity, gastrointestinal survival, and stability throughout shelf life. The capacity of both the fermented beverages and the capsules to reduce incidences of antibiotic-associated diarrhea and Clostridium difficile infection (CDI) has been demonstrated in human clinical trials. Individual strains and the finished products have shown antimicrobial activity against C. difficile and toxin A/B neutralization capacity in vitro. The use of this specific probiotic formulation as part of a bundle of preventive measures to control CDI in healthcare settings is discussed.
一种特定的益生菌配方，由嗜酸乳杆菌 CL1285、干酪乳杆菌 LBC80R 和鼠李糖乳杆菌 CLR2（Bio-K+）组成，自 1996 年以来一直在北美市场销售。这些菌株和商业产品已经过安全性、身份、胃肠道存活和整个保质期稳定性的评估。发酵饮料和胶囊都能降低抗生素相关性腹泻和艰难梭菌感染（CDI）的发生率，这已在人体临床试验中得到证实。在体外，单个菌株和成品对艰难梭菌具有抗菌活性，能够中和毒素 A/B。本文讨论了将这种特定的益生菌配方作为预防措施的一部分，用于控制医疗机构中的 CDI。
